Improving Patient Outcomes with Novel Treatment Strategies in the Management of Multiple Sclerosis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session at the 2017 Spring Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 15, 2017 to August 1, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This educational activity is supported by educational grants from
AbbVie Inc., Biogen, Celgene Corporation,
Novartis Pharmaceuticals, and Teva Pharmaceuticals

Multiple Sclerosis (MS) is a chronic progressive disease and is the most common neurological cause of disability among young adults throughout the United States. In many cases, multiple sclerosis may not be diagnosed for months to years after the onset of symptoms. Some strategies for diagnosis include a careful medical history, a neurologic exam and various tests, including magnetic resonance imaging (MRI), evoked potentials (EP) and spinal fluid analysis. Although there is no cure for MS there have been numerous revisions to MS diagnostic criteria as many advances in treatment have arrived in recent years, allowing patients to manage their symptoms and improve their quality of life. These agents provide physicians with even more options and delivery methods for managing MS. Clinical data shows these agents have the ability to improve outcomes in efficacy as it relates to the management of patients with MS. A number of factors must be considered when selecting a treatment regimen for patients with MS, including variations in clinical and MRI evidence of disease.

Upon Completion of this activity, participants will be able to:

  • Evaluate the mechanisms of action and efficacy and safety profiles of current and emerging therapies to develop individualized multiple sclerosis (MS) plans that optimize adherence and improve patient outcomes

  • Assess the factors involved when establishing MS therapeutic strategies including patient, disease, and treatment characteristics that factor into MS treatment selection and considerations for predicting treatment response and identifying when to switch therapies

  • Examine strategies to identify MS earlier in the disease course to initiate more timely treatment and promote disease inactivity

  • Apply newer MRI criteria and other prognostic measures to improve diagnosis and therapy initiation earlier in the course of MS

  • Develop individualized plans to monitor and manage adverse events associated with MS therapies in order to improve patient adherence, safety and outcomes

  • Apply methods to enable optimal cost management of current and emerging therapies to be realized by multiple MS stakeholders including medical directors and managed care organizations

Faculty: Gary Owens, MD
Gary Owens Associates


Dr. Owens serves as a consultant AbbVie, Biogen, Novartis and Roche. His presentation has been peer reviewed.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Katie Eads has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation

The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM. Each physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This educational activity is supported by educational grants from
AbbVie Inc., Biogen, Celgene Corporation,
Novartis Pharmaceuticals, and Teva Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue